Becton Dickinson and Company
Becton Dickinson and Company/ US0758871091 /
BDX
16/08/2024 19:32:12
|
Chg.
+2.51
|
Volume |
Bid19:32:25 |
Ask19:32:25 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
236.53USD
|
+1.07%
|
367,445 Turnover: 56.78 mill. |
236.48Bid Size: 100 |
236.67Ask Size: 400 |
68.19 bill.USD |
1.54% |
47.47 |
Business description
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. The innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes.
Management board & Supervisory board
CEO |
Tom Polen |
Management board |
Christopher DelOrefice, Ami Simunovich, Dave Hickey, David Shan, Elizabeth McCombs, Roland Goette, William R. Sigmund, II, Michelle Quinn, Shana Neal, Pavan Mocherla, Vishy Kanda, Michael Garrison, Denise Fleming, Tony Ezell, Richard Byrd, Herman Cueto, Jeff Silvestri |
Supervisory board |
Tom Polen, Bertram L. Scott, Timothy M. Ring, Marshall O. Larsen, Christopher Jones, Jeffrey W. Henderson, Claire M. Fraser, R. Andrew Eckert, Carrie Byington, Catherine M. Burzik, William M. Brown, Joanne Waldstreicher |
Company data
Name: |
Becton, Dickinson and Company |
Address: |
1 Becton Drive,Franklin Lakes, New Jersey 07414, USA |
Phone: |
+1-201-847-6800 |
Fax: |
- |
E-mail: |
-
|
Internet: |
www.bd.com |
Industry: |
Healthcare |
Sector: |
Medical Products |
Sub sector: |
Advanced Medical Devices |
End of financial year: |
30/09 |
Free Float: |
77.40% |
IPO date: |
23/04/1962 |